The design and synthesis of related molecules that are more effective, more selective, and less toxic than aspirin are important objectives of biomedical research.name: 2,4-Dimethylpyridine, If a proposed mechanism predicts the wrong experimental rate law, however, the mechanism must be incorrect.Welcome to check out more blogs about 108-47-4, in my other articles.
name: 2,4-Dimethylpyridine, Chemical engineers work across a number of sectors, processes differ within each of these areas, and are directly involved in the design, development, creation and manufacturing process of chemical products and materials. 108-47-4, Name is 2,4-Dimethylpyridine, molecular formula is C7H9N. In a Article,once mentioned of 108-47-4
Three previously unreported forms of complexes of CuI with a pyridine derivative have been isolated and examined by single-crystal X-ray techniques: (1) (3Me-py = 3-methylpyridine), stoicheiometry 1:1:2, monoclinic space group P21, a=7.912(2), b=19.390(6), c=8.774(2) Angstroem, beta=102.22(2)o, Z=2, R=0.047 for 2072 observed reflections, crystallizes with isolated rhombohedra of Cu2I2, each Cu being co-ordinated to two ligand molecules via nitrogen atoms; <> (2) and <> (3) (2,4Me2-py = 2,4-dimethylpyridine), stoicheiometries 1:1:1, (2), monoclinic space group P21/a, a=11.834(5), b=14,914(6), c=4.381(2) Angstroem, beta=93.80(4)o, Z=4, R=0.078 for 1082 reflections, (3), triclinic space group P1, a=11.648(8), b=4.328(3), c=10.198(4) Angstroem, alpha=77.64(5), beta=68.45(4), gamma=104.25(5)o, R=0.063 for 1731 reflections.Both (2) and (3) crystallize as edge-sharing Cu2I2 rhombs, with each copper atom bound to three iodide atoms and the nitrogen atom of a molecule of the Lewis base.
The design and synthesis of related molecules that are more effective, more selective, and less toxic than aspirin are important objectives of biomedical research.name: 2,4-Dimethylpyridine, If a proposed mechanism predicts the wrong experimental rate law, however, the mechanism must be incorrect.Welcome to check out more blogs about 108-47-4, in my other articles.
Reference:
Chiral nitrogen ligands in late transition metal-catalysed asymmetric synthesis—I. Addressing the problem of ligand lability in rhodium-catalysed hydrosilations,
Nitrogen-Containing Ligands for Asymmetric Homogeneous and Heterogeneous Catalysis